Hey GMIN, the general demeanor in your posts, for my

New Post Public Reply Private Reply Replies (1) Message Board
Zolis_onkel GMIN #30129
474
Hey GMIN,

the general demeanor in your posts, for my taste, is in general a little bit too negative. While I agree with some of what you wrote, I personally would not want to spill the baby with the water, as we say here in Germany.

Let me reply to your points one by one.

* continued poor communication. I guess we can all agree on that. Joe's bragging about full transparency and the best communication ever seen in a company, compared to the current reality does not reflect what I would consider great communication of a company to its shareholders. I fully agree with that, and especially the "no follow-ups" is exactly one of the biggest problems that I see. Promising something to happen "soon", or within a certain time frame, and then not at all hearing about it again, is surely one of THE MAIN things that frustrates me as well about the company's communication with us.

* Class A/B, NGIO IPO. I do not fully agree there. For sure it sounded very different when we were told that we, GNBT shareholders, would receive NGIO shares as a dividend. For sure I was not expecting that we have to wait more than 1.5 years for the NGIO IPO, and once the shares would finally start trading, that I have to wait another - up to - 1.5 years, before I can cash in on this dividend.
With that said, however, I do not agree with you on the fact that the Class A NGIO shareholders would not immediately benefit from the IPO, and that it would be a double loss. I actually have not doubt in my mind that right after the IPO the GNBT share price (and Class A shareholders have to be GNBT shareholders also, or at least once were, because the only way to receive Class A was via the GNBT dividend.) will significantly increase, for two reasons in particular.
1) the value of the NGIO shares that GNBT continues to hold, will definitely be made visible, and
2) the capital that GNBT will generate from this IPO will surely stop the steady bleeding dilution just to cover operating expenses, as well as it makes the necessary funding available to close the deal on AltuCell, jump start the Excellagen market roll-out (why that has actually not happened via the CC announced financing, or at least why we haven't been informed about it, is beyond my comprehension), fund further activities in regards to the RPM etc. So these are all very good reasons why the GNBT PPS will increase due to the IPO. This in fact is the reason why I think that this is one of the most important things that GNBT's management should get this done ASAP.
And besides the Class A NGIO shares will, by no means be worthless. Each of these shares represents a fractional ownership to the NGIO company. In the best of all cases, they get their "Complete Vaccine" FDA approved, and it turns out to be a block buster, and the NGIO share price sky rockets at least as much as the NVAX PPS did after the BARDA approval announcement. And then you have shares worth $100/sh or more in your broker account, the only thing is that you have to wait another couple of months before you can cash in on them. Just because the SevenEleven store is closed today, and you have to wait until 7 a.m. tomorrow, you do not trash your winning lottery ticket, right? So I do not really understand that statement "worthless Class A shares".
*NUGX of no interest to GNBT management. Not at all true. The only thing is that they seem to not be able to do much about it as of now. They can only react to it. And you might have read Joe's statement on here, that it is the person's fault, who started the NUGX trading, that they now had to make the distinction between Class A/B NGIO shares. This is for sure Joe's concern, and very likely is - at least one of - the reason(s) why the IPO got delayed once again.
With all that happened to GNBT in this regard, there really seem to be serious forces at play, that seem to be trying everything they can to stop GNBT from making progress, and maybe one day realize its own uplist to Nasdaq. For sure there are mistakes that Joe and his team made, but for sure there are also things that have happened that are out of GNBT's control, that got us all, where we are today.
* a joke? If you consider all of this a joke? Well, then your sense of humor must be very much different from mine, because I can honestly not laugh about this current situation anymore, and I would surely like to see a reversal of the pps trajectory better yesterday than today, but no later than tomorrow, and for sure not "soon", as the "soon" still seems to be too vague and far away, at least in Joe's obvious time scales.

Still there is not just black and white to see here, but rather still a lot of shades of gray inbetween. Still, GNBT management, please send us a follow up to all the positive leads you shared with us during the CC, which is already a month ago already! I think we all deserve an update. THANK YOU VERY MUCH!

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Taseko Mines Earnings: Missed Estimates or Surprising Upside?

Updated Category News Views 144

Taseko Mines (AMEX:TGB) is set to drop its quarterly earnings report on February 18, 2026, and traders are already buzzing about it. The whispers in the hallways suggest a glimmer of hope, with analysts eyeing an earnings per share (EPS) of $0.08—a target that could shift market sentiments depending on how it lands. The last quarter's performance still stings; Taseko...

Continue Reading
Magnet Biomedicine Enhances Research with Simplicis's Ledger™

Updated Category News Views 173

Magnet Biomedicine Partners with Simplicis's Ledger™ Platform Magnet Biomedicine, a pioneering biotechnology firm focused on advancing molecular glue discovery, has recently chosen Simplicis's Ledger™ platform following a thorough assessment of leading alternatives. This decision reflects a commitment to enhancing research operations and optimizing compound management...

Continue Reading
Forecasting Asset Appreciation: Bitcoin and Gold's Potential Rise

Updated Category News Views 114

Understanding Market Dynamics Under Uncertain Political Landscapes In the world of finance, significant political changes can lead to substantial shifts in market dynamics. Recent insights from JPMorgan analysts suggest that a victory for Donald Trump could lead to a spike in both Bitcoin and gold prices. This projection is rooted in growing interest from retail investors...

Continue Reading
Apple and Google Forge a Powerful AI Partnership for Future

Updated Category News Views 73

Apple and Google's Exciting AI Collaboration With the excitement surrounding artificial intelligence expected to surge into 2026, tech enthusiasts and market analysts alike are keenly observing the landscape. The anticipation is mounting as companies evaluate their AI capabilities, looking to distinguish true leaders from those merely riding the wave of hype. In a...

Continue Reading
Podcasting Industry Set to Hit $114 Billion With New Trends

Updated Category News Views 241

Explosive Growth in the Podcasting Market Podcasting continues to gain massive traction, with predictions estimating the market will skyrocket from USD 31.49 billion now to an impressive USD 114.48 billion by 2030. This remarkable growth, with a compound annual growth rate (CAGR) of 29.45%, is driven by several innovative trends reshaping the media landscape....

Continue Reading